Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma

BACKGROUND: To evaluate the efficacy and safety of everolimus, a mTOR inhibitor, on invasive malignant renal epithelioid angiomyolipoma (EAML). MATERIALS AND METHODS: From Oct 2014 to May 2019, we collected data from seven patients with a definite (clinical and pathological) diagnosis of EAML receiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Gang, Gu, Liangyou, Zhang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870865/
https://www.ncbi.nlm.nih.gov/pubmed/33575217
http://dx.doi.org/10.3389/fonc.2020.610858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870865/
https://www.ncbi.nlm.nih.gov/pubmed/33575217
http://dx.doi.org/10.3389/fonc.2020.610858

Ejemplares similares